Nora Shoaip1, Amira Rezk1, Shaker EL-Sappagh2,3, Tamer Abuhmed4,*, Sherif Barakat1, Mohammed Elmogy5
CMC-Computers, Materials & Continua, Vol.69, No.3, pp. 3531-3548, 2021, DOI:10.32604/cmc.2021.019069
- 24 August 2021
Abstract Alzheimer’s disease (AD) is a very complex disease that causes brain failure, then eventually, dementia ensues. It is a global health problem. 99% of clinical trials have failed to limit the progression of this disease. The risks and barriers to detecting AD are huge as pathological events begin decades before appearing clinical symptoms. Therapies for AD are likely to be more helpful if the diagnosis is determined early before the final stage of neurological dysfunction. In this regard, the need becomes more urgent for biomarker-based detection. A key issue in understanding AD is the need… More >
Login
Register
